Table 4.
Combination therapies in WM including nucleoside analogues with alkylating agents and rituximab
| Study | Regimen | N | Phase | ORR % |
|---|---|---|---|---|
| Tam (96) | Fludara/CTX | 9 | II | 88 |
| Tamburini (43) | Fludara/CTX | 49 | II | 78 |
| Weber (32) | Cladribine/CTX | 37 | II | 84 |
| Tam (44) | Fludara/CTX/rituximab | 5 | II | 80 |
| Weber (32) | Cladribine/CTX/rituximab | 27 | II | 94 |
| Hensel (97) | Pentostatin/CTX/rituximab | 17 | II | 90 |
Phase, phase of study; N, number of patients; ORR, overall response rate; CR, complete response; %, percentage.